The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 9.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 34% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (19 analysts) rates it buy, with a mean price target of $49. Since the last review it dropped out of the Titan Ethical 500.
Bayer AG
BAYN.DE · XETRA · EUR · Market cap $35.6B · 87,757 employees
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil.
FAIL · Does not pass the screenPrice as of 13 Nov 2026Daily close, not a live quote
Screened 2026-11-13 · the tape above runs as of 08:09 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price56.52 EUR at the 13 Nov 2026 close
- Our value readOvervalued vs our fair value, as of 13 Nov 2026
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenDoes not pass
- Last reviewed13 Nov 2026 (3 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: 37.76 EUR to 61.37 EUR, base estimate 47.24 EUR (screen dated 2026-11-13).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Bayer AG holds its Markup at $56.52. Consolidating, no directional conviction, held for 10 days.
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 10 days |
| Price at the screen | $56.52 |
| Valuation | N/A trailing · 10.39 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 0.85 |
Five Screens, Shown in Full
Does not pass. Debt ratio 34.9%
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 34.87% | Below 33% | Interest-bearing debt is 34.9% of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | 6.38% | Below 33% | Cash held in interest-bearing accounts and securities is 6.4% of assets, under the one-third limit. | Pass |
| Receivables | 8.68% | Below 49% | Money owed to the company is 8.7% of assets, under the 49% limit. | Pass |
| Revenue purity | 4.07% | Below 5% | Only 4.1% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Bayer's business is in a permissible area, but its interest-bearing debt is about 35% of the company, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-15. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when BAYN.DE's ethical verdict changes
Today BAYN.DE does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 13 Nov 2026: it trades above our 47.24 EUR fair value estimate.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in EUR, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. The price runs 19.6% above the base estimate.
Third-party analyst targets: 19 covering, consensus Buy. The average target sits −8% from the screen price.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & ProjectionsWhere our models see it going: fair-value estimate 47.24 EUR, with a range of 37.76 EUR to 61.37 EUR, dated to the 2026-11-13 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsWhy it gives us pause
At 10.4x forward earnings, the price already runs ahead of the business. It trades 20% above our 47.24 EUR fair value, so you would be buying at a premium, not a discount.
| Forward P/E | 10.4xreasonably valued |
| EPS, trailing | -2.19 |
| EPS, forward | 4.72 |
| Revenue growth | -2.4%revenue is shrinking |
| Profit margin | -4.8%currently unprofitable |
| Return on equity | -6.9%not currently earning a positive return on equity |
| FCF yield | 23.49% |
| Dividend yield | 0.29% |
| Debt to equity | 1.34a meaningful debt load worth watching |
| Beta | 0.85steadier than the market |
| 52-week range | 24.81 - 49.78 |
| Market cap | $35.6B |
| Employees | 87,757 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: its business and earnings are exposed to Germany and to currency swings; as a drug manufacturers - general name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeBAYN.DE trades on XETRA (the company is based in Germany). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (19 analysts) rates it buy, with a mean price target of $49.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (19 analysts) rates it buy, with a mean price target of $49.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (19 analysts) rates it buy, with a mean price target of $49.
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 35.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (19 analysts) rates it buy, with a mean price target of $49. Since the last review it its composite score eased.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (19 analysts) rates it buy, with a mean price target of $49.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (19 analysts) rates it buy, with a mean price target of $49.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 8% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 33%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (19 analysts) rates it buy, with a mean price target of $49.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $37.08 | -4.6% | · | $954 | -4.6% |
| 2 months | $40.01 | -11.6% | $0.11 | $887 | -11.3% |
| 3 months | $39.90 | -11.4% | $0.11 | $889 | -11.1% |
| 6 months | $36.23 | -2.4% | $0.11 | $979 | -2.1% |
| 1 year | $26.67 | +32.6% | $0.11 | $1,330 | +33.0% |
| 2 years | $27.27 | +29.7% | $0.22 | $1,305 | +30.5% |
| 3 years | $50.56 | -30.0% | $0.33 | $706 | -29.4% |
| 5 years | $49.11 | -28.0% | $4.73 | $817 | -18.3% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever BAYN.DE does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.